Literature DB >> 6823561

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.

J W Langston, P Ballard, J W Tetrud, I Irwin.   

Abstract

Four persons developed marked parkinsonism after using an illicit drug intravenously. Analysis of the substance injected by two of these patients revealed primarily 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) with trace amounts of 1-methyl-4-phenyl-4-propionoxy-piperidine (MPPP). On the basis of the striking parkinsonian features observed in our patients, and additional pathological data from one previously reported case, it is proposed that this chemical selectively damages cells in the substantia nigra.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6823561     DOI: 10.1126/science.6823561

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  909 in total

1.  Neuropsychological abnormalities in first degree relatives of patients with familial Parkinson's disease.

Authors:  K Dujardin; A Duhamel; E Becquet; C Grunberg; L Defebvre; A Destee
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

Review 2.  NMDA receptors in the basal ganglia.

Authors:  P Ravenscroft; J Brotchie
Journal:  J Anat       Date:  2000-05       Impact factor: 2.610

3.  Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users.

Authors:  A C Parrott; T Buchanan; T M Heffernan; A Scholey; J Ling; J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  2003-04-08       Impact factor: 4.530

Review 4.  Glial cell response: A pathogenic factor in Parkinson's disease.

Authors:  Du Chu Wu; Kim Tieu; Oren Cohen; Dong-Kug Choi; Miquel Vila; Vernice Jackson-Lewis; Peter Teismann; Serge Przedborski
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

5.  Real-time monitoring of superoxide generation and cytotoxicity in neuroblastoma mitochondria induced by 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline.

Authors:  Sarah Jayne Boulton; Paul C Keane; Christopher M Morris; Calum J McNeil; Philip Manning
Journal:  Redox Rep       Date:  2012-05-30       Impact factor: 4.412

6.  PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.

Authors:  Bin Zheng; Zhixiang Liao; Joseph J Locascio; Kristen A Lesniak; Sarah S Roderick; Marla L Watt; Aron C Eklund; Yanli Zhang-James; Peter D Kim; Michael A Hauser; Edna Grünblatt; Linda B Moran; Silvia A Mandel; Peter Riederer; Renee M Miller; Howard J Federoff; Ullrich Wüllner; Spyridon Papapetropoulos; Moussa B Youdim; Ippolita Cantuti-Castelvetri; Anne B Young; Jeffery M Vance; Richard L Davis; John C Hedreen; Charles H Adler; Thomas G Beach; Manuel B Graeber; Frank A Middleton; Jean-Christophe Rochet; Clemens R Scherzer
Journal:  Sci Transl Med       Date:  2010-10-06       Impact factor: 17.956

Review 7.  Mitochondria, OxPhos, and neurodegeneration: cells are not just running out of gas.

Authors:  Estela Area-Gomez; Cristina Guardia-Laguarta; Eric A Schon; Serge Przedborski
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

8.  Mitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice.

Authors:  Lee J Martin; Samantha Semenkow; Allison Hanaford; Margaret Wong
Journal:  Neurobiol Aging       Date:  2013-11-16       Impact factor: 4.673

9.  Synergistic interactions between NMDA-antagonists and L-dopa on activity in MPTP-treated mice.

Authors:  A Fredriksson; C Gentsch; T Archer
Journal:  J Neural Transm Gen Sect       Date:  1994

10.  Neurotoxic damage to the nigrostriatal system in rats following intranigral administration of MPDP+ and MPP+.

Authors:  C J Sun; J N Johannessen; W Gessner; I Namura; W Singhaniyom; A Brossi; C C Chiueh
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.